 DURHAM, N.C., March 29, 2021 GLOBE NEWSWIRE -- Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines Rare Disease Day on April 1, 2021. 